GHK-Cu: what the research shows

GHK (glycyl-L-histidyl-L-lysine) is a tripeptide found in human plasma, saliva, and urine that binds copper. GHK-Cu is used in topical cosmetic products; there is no FDA-approved injectable drug containing it.[1][2]

What the research covers

Reviews by L. Pickart and colleagues describe effects on collagen and glycosaminoglycan synthesis, metalloproteinase activity, and wound healing in animal models, and report cosmetic study results such as improved skin firmness and reduced fine lines.[1][3] These reviews come from authors at a skin-care company’s research department, and broad claims such as regulating at least 4,000 human genes come from those reviews rather than from clinical trials.[1]

Topical versus injectable

The published human data are mostly topical and cosmetic. FDA treats the two routes differently. It lists GHK-Cu for injectable routes among substances previously placed in category 2 whose nominations were withdrawn, citing aggregation and impurity risk and stating “there are limited data in humans to inform safety-related considerations.”[4] Since May 2026, GHK-Cu for non-injectable routes has been in category 1, “under evaluation,” on FDA’s list of substances nominated for pharmacy compounding: FDA says one nominator clarified on May 5, 2026, that it meant to withdraw only its nomination for the injectable route. Category 1 is not an approval.[10]

Human trials

As a wound drug (Iamin gel), GHK-Cu did no better than placebo in a 1992 trial in 86 people with venous leg ulcers, and its developer ProCyte reported in October 1994 that a 511-patient Phase III trial in diabetic foot ulcers showed no significant benefit. ProCyte then obtained FDA clearance for Iamin gel as an over-the-counter wound dressing in 1996, a device route based mainly on safety.[6][7] A 2006 randomized study of GHK-Cu skin products after laser resurfacing (13 completers) found no objective difference.[8] A 2016 split-face trial in 40 women, funded by the serum’s maker, found wrinkle volume fell more with a GHK-Cu nano-carrier serum than with the plain serum base (24.1% versus 15.0%).[9] For the full paper trail, see our GHK-Cu teardown.

Regulatory status

A Drugs@FDA search returns no approved drug application containing GHK-Cu.[2] A 2026 review lists GHK-Cu among peptides marketed directly to patients without approval.[5] FDA says it intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027 about whether GHK-Cu belongs on the 503A bulks list.[10] Our FDA peptide status tracker shows where GHK-Cu stands next to other peptides.

What is not known

There are no controlled trials of injected GHK-Cu with clinical outcomes and no established injectable dose.[4][5]

References

Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. PMID 26236730. https://pubmed.ncbi.nlm.nih.gov/26236730/. Checked October 15, 2026.
U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs database (searched by ingredient name via the openFDA drugsfda endpoint). https://www.accessdata.fda.gov/scripts/cder/daf/. Checked October 15, 2026.
Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19(8):969-88. PMID 18644225. https://pubmed.ncbi.nlm.nih.gov/18644225/. Checked October 15, 2026.
U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2 of the bulk substances nominated under sections 503A or 503B). Content current as of April 22, 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks. Checked October 15, 2026.
Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026;56(8):1921-1935. PMID 41966639. https://pubmed.ncbi.nlm.nih.gov/41966639/. Checked October 15, 2026.
Bishop JB, Phillips LG, Mustoe TA, et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg. 1992;16(2):251-257. PMID 1495150. https://pubmed.ncbi.nlm.nih.gov/1495150/. Checked October 16, 2026.
ProCyte Corporation. Annual report on Form 10-K for 1995, filed March 25, 1996 (Phase III, 511 patients, “disappointing results”; 510(k) clearance of Iamin gel as an OTC wound dressing, February 1996). https://www.sec.gov/Archives/edgar/data/856072/0000912057-96-005087.txt. Checked October 16, 2026.
Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-259. PMID 16847171. https://pubmed.ncbi.nlm.nih.gov/16847171/. Checked October 16, 2026.
Badenhorst T, Svirskis D, Merrilees M, Bolke L, Wu Z. Effects of GHK-Cu on MMP and TIMP expression, collagen and elastin production, and facial wrinkle parameters. J Aging Sci. 2016;4(3):166. doi:10.4172/2329-8847.1000166 (funded by Snowberry New Zealand Ltd). https://doi.org/10.4172/2329-8847.1000166. Checked October 16, 2026.
U.S. Food and Drug Administration. “Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act,” categories 1–3, updated May 14, 2026. Category 1 (“Bulk Drug Substances Under Evaluation”) lists “GHK-Cu (except for injectable routes of administration)”; the update note says that “on May 5, 2026, one of those nominators clarified that it intended to withdraw only its nomination of the injectable route of administration” and that FDA “intends to consult the Pharmacy Compounding Advisory Committee (PCAC) before the end of February 2027 regarding the potential inclusion of GHK-Cu on the 503A bulks list.” https://www.fda.gov/media/94155/download. Checked October 24, 2026.

This page summarizes published research and regulatory documents. It is not medical advice and does not recommend using, sourcing, or dosing any of these substances.